A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
This study, called TG4050, is looking into a new treatment for a type of head and neck cancer. Specifically, it's for squamous cell carcinoma, which has been removed by surgery. This is an early-stage study, meaning researchers are mainly checking if the treatment is safe and if people can tolerate it well. They'll also be looking for early signs of how well it works. The study includes different surgery types for patients who have already had their main tumour removed and are now in complete remission. It aims to see if TG4050 can help prevent the cancer from coming back.
At a glance
What is this study about?
This study is called TG4050 and it's looking at a new treatment for a specific type of head and neck cancer called squamous cell carcinoma. This cancer can affect areas like the mouth, throat, or voice box. The researchers want to understand how safe this new treatment is and if it causes any side effects. They'll also be looking to see early signs of whether it helps patients.
The study is for people who have recently been diagnosed with this type of cancer in stages III or IV, but only if their cancer can be treated with surgery. Importantly, patients taking part in this study must have already had their main cancer successfully removed by surgery and be showing no signs of cancer at that point. The aim is to see if TG4050 can help keep the cancer from returning after initial treatment.
This is an early-stage study (Phase I/II), which means it's one of the first times this treatment is being tested in humans. Studies like this are vital for finding new and better ways to treat cancer, but because it's new, we don't yet know all the effects it might have.
Key takeaways
- Tests a new treatment (TG4050) for head and neck cancer.
- For patients whose cancer has been successfully removed by surgery.
- Focuses on safety and early signs of effectiveness.
- It's an early-stage study (Phase I/II).
- Requires regular hospital visits and check-ups.
Who may be eligible?
To join this study, you must be at least 18 years old and have been recently diagnosed with stage III or IV squamous cell carcinoma of the mouth, throat, or voice box that can be treated with surgery. A key requirement is that you must have already had your main tumour successfully removed by surgery and are now completely clear of cancer. You also need to be generally in good health and able to carry out your daily activities without much difficulty.
There are certain reasons why you wouldn't be able to join. For example, if your cancer started in your nose, skin, or salivary glands, or if it's a different type of cancer. You also can't have had certain previous cancer treatments, especially other vaccines or specific immune-boosting drugs. If you have other serious uncontrolled illnesses, or certain infections like HIV or hepatitis, you wouldn't be eligible. Pregnant or breastfeeding women also cannot take part in this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have stage III or IV squamous cell head and neck cancer that has been removed by surgery?
- Are you currently free of cancer after your surgery?
- Are you generally in good health and able to do your daily activities?
- Are you NOT pregnant or breastfeeding?
What does participation involve?
If you take part in this study, you will likely have regular hospital visits for check-ups and to receive the TG4050 treatment. These visits will involve various tests, such as blood tests, to monitor your health and how the treatment is affecting you. You'll also have scans to check if the cancer remains clear. The doctors and nurses will closely monitor you for any side effects. The exact number of visits and the total length of time you'll be involved can vary, but studies like this often last for several months to a few years to track your progress after treatment. You'll be given detailed information about the schedule if you're considered for the study.
Potential risks and benefits
Locations (14)
- Mayo Clinic JacksonvilleVerified postcodeJacksonville, United States
- Hôpital Saint André - CHU de BordeauxVerified postcodeBordeaux, France
- Hôpital de la TimoneVerified postcodeMarseille, France
- Institut CurieVerified postcodeParis, France
- IUCT ToulouseVerified postcodeToulouse, France
- Institut Gustave RoussyVerified postcodeVillejuif, France
- Hospital Universitari Vall d HebrónVerified postcodeBarcelona, Spain
- Institut Català d Oncologia - Hospital Duran i ReynalsVerified postcodeBarcelona, Spain
- Hospital Clínico San CarlosVerified postcodeMadrid, Spain
- Hospital Universitario La PazVerified postcodeMadrid, Spain
- Hospital Regional Universitario de Málaga - Hospital CivilVerified postcodeMálaga, Spain
- Complejo Hospitalario Universitario de SantiagoVerified postcodeSantiago de Compostela, Spain
Common questions
What kind of cancer is this study for?
It's for a specific type of head and neck cancer called squamous cell carcinoma, affecting areas like the mouth, throat, or voice box.
What stage of cancer is this study looking at?
It's for newly diagnosed stage III or IV cancer, but only if it has already been successfully removed by surgery.
What is TG4050?
TG4050 is the name of the new treatment being tested in this study. It's a type of experimental drug.
Is this treatment guaranteed to work?
No, this is an early-stage study, so we don't know for sure if it will work or if it's better than current treatments. Researchers are testing its safety and early effectiveness.
Can I stop participating in the study if I want to?
Yes, you can leave the study at any time, for any reason, without it affecting your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.